OLIPASS CORPORATION

Other languages OLIPASS Corporation

Equities

A244460

KR7244460002

End-of-day quote Korea S.E. Other stock markets 03:30:00 07/06/2024 am IST			5-day change	1st Jan Change
481 ^KRW	+2.12%		-0.21%	-37.86%

18/03	OLIPASS Corporation announced that it has received KRW 3.5 billion in funding	CI
06/03	OLIPASS Corporation announced that it expects to receive KRW 5 billion in funding	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

OliPass Corporation Discloses Painful But Hilarious Clinical Findings from a Phase 2a Trial in OA Patients with Nav1.7 Selective Inhibitor OLP-1002	13/11
OLIPASS Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	20/23/20
OliPass Corporation Announces Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy and Long Therapeutic Duration According to Interim Findings from Phase 2A Study in OA Patients	16/23/16
Vanda Pharmaceuticals Inc. and OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide Therapeutics	30/22/30
OliPass Corporation Moves Forward to Second Stage of Phase 2a Trial for Pain Killer OLP-1002	18/22/18
OliPass Corporation Announces Commencement of Dosing in Phase 2a Trial for Pain Killer OLP-1002	18/22/18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer